Call for Abstract
Scientific Program
4th International Conference and Exhibition on Pharmacovigilance & Clinical Trials, will be organized around the theme “Reviving Strategies for Safer Therapeutics in Healthcare System”
Pharmacovigilance-2015 is comprised of 12 tracks and 65 sessions designed to offer comprehensive sessions that address current issues in Pharmacovigilance-2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Significance of pharmacovigilance
- Track 1-2Pharmacovigilance and healthcare system
- Track 1-3Pharmacovigilance legislation
- Track 1-4Role of pharma industries in the improvement of pharmacovigilance system
- Track 1-5Detection and evaluation of drug safety signals through manual and medical devices reporting
- Track 1-6Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines
- Track 1-7Methods of pharmacovigilance
- Track 2-1Designing of trials: pre-clinical studies and different phases of clinical trials
- Track 2-2Bioassay and its types
- Track 2-3Data collection and quality control
- Track 2-4Alternative trials design and models
- Track 2-5Multi center trials and monitoring
- Track 2-6Regulatory authorities and ethics committee
- Track 2-7Advanced Information technology in clinical trials and promoting companies
- Track 2-8Clinical trials on drugs used in respiratory disorders
Track 3:Clinical Trials on Drugs used in Various Disorders, Pharmacotherapy and Pharmacotherapeutics
- Track 3-1Emerging technology in clinical trials
- Track 3-2Recent clinical trials on AIDS
- Track 3-3Clinical trials on benign and malignant tumors
- Track 3-4Clinical trials on cardiovascular diseases
- Track 3-5Clinical trials on diabetes
- Track 3-6Clinical trials of monoclonal and polyclonal antibodies
- Track 3-7Clinical trials on drugs used in psychological disorders
- Track 3-8Applications of biomarkers in clinical trials
- Track 4-1Classification of various adverse drug reactions
- Track 4-2Mechanism of adverse drug reactions
- Track 4-3Assessing and reporting adverse drug reactions
- Track 4-4Expected and un-expected drug reactions and its reporting
- Track 4-5Pharmacogenomics
- Track 4-6Post marketing reports on adverse effects
- Track 4-7Reduction of adverse drug reaction by nanotechnology
- Track 5-1Advances in pharmacokinetic interactions
- Track 5-2Advances in pharmacodynamic interactions
- Track 5-3Drug and substance abuse
- Track 5-4Drug-drug interactions
- Track 6-1Pharmacy practice and its guidelines
- Track 6-2Challenges in compounding and dispensing practice
- Track 6-3Dosage regimen, drug toxicity and drug safety measures
- Track 6-4Pharmacoepidemiology of drug shortages
- Track 7-1Information technology in pharmacovigilance and promoting companies
- Track 7-2Review of softwares used in pharmacovigilance and clinical trials
- Track 7-3Risk communication: Interface between pharmacovigilance, sales and marketing
- Track 7-4Monitoring unlicensed, off labels and orphan drugs
- Track 8-1ICH guidelines for clinical research and its statistics
- Track 8-2Data mining concepts and techniques
- Track 8-3Stastical analysis of past pharmacovigilance and adverse drug reactions reports
- Track 8-4SAS Programing in Clinical Research and Pharmacutical Industry
- Track 8-5Role of Regulatory Affairs in Clinical Research
- Track 9-1Strategic development towards FDA approval
- Track 9-2Post market product surveillances
- Track 9-3Advances in changing pharmacovigilance regulation system
- Track 10-1Role of pharmacovigilance and pharmacoepidemiology in risk management
- Track 10-2Good reporting practices
- Track 10-3Signal investigation via observational studies
- Track 10-4Interpreting safety signals
- Track 10-5Randomized clinical trials
- Track 11-1Unique therapeutic approaches
- Track 11-2Cancer case reports
- Track 11-3Cardiovascular trials case report
- Track 11-4Case studies on sexually transmitted diseases
- Track 11-5Case studies on type 1 and type 2 diabetes
- Track 11-6Case reports on drugs used in pregnancy and lactation
- Track 12-1Rational drug management of cancer, diabetes and cardiovascular disorders
- Track 12-2Management of psychiatric disorders and autoimmune disorders
- Track 12-3Bioavailaibility and bioequivalence
- Track 12-4Invivo-invitro correlation